Health Equity in Clinical Trials Best Practices Database
Recognizing that many companies in New Jersey and beyond are dedicated to increasing diversity in clinical trials, BioNJ created this platform where life sciences professionals can go to search best practices, ascertain successful strategies and learn about initiatives that are underway.
Select from below to see initiatives.
| CompanyName | Company | Initiative | Category | link | Title | Description | Article |
|---|---|---|---|---|---|---|---|
| Bristol Myers Squibb | https://s25.q4cdn.com/566753351/files/design/bms-rebrand-logo.svg | WORKFORCE DEVELOPMENT (e.g., investigator education & diversity) | https://investors.bms.com/iframes/press-releases/press-release-details/2023/Bristol-Myers-Squibb-Inducted-into-the-Billion-Dollar-Roundtable-Expands-Supplier-Diversity-Efforts/default.aspx | Bristol Myers Squibb Inducted into the Billion Dollar Roundtable, Expands Supplier Diversity Efforts | Bristol Myers Squibb Inducted into the Billion Dollar Roundtable, Expands Supplier Diversity Efforts | BMS has been inducted into the Billion Dollar Roundtable. This milestone highlights BMS' longstanding history of taking purposeful action to advance health equity, foster a diverse and inclusive workplace, improve and increase the diversity in its clinical trials and expand the diversity among its supplier base. | |
| AJMC | https://files.constantcontact.com/971a6f79001/df2be55d-a15a-4124-a427-8c6ce966c387.png | WORKFORCE DEVELOPMENT (e.g., investigator education & diversity) | https://www.ajmc.com/view/expanding-access-to-clinical-trials-through-community-partnerships | Expanding Access to Clinical Trials Through Community Partnerships | Karen Winkfield, MD, PhD, addresses the importance of meeting patients where they are to expand clinical trial participation and remove barriers to trial access. | Karen Winkfield, MD, PhD, addresses the importance of meeting patients where they are to expand clinical trial participation and remove barriers to trial access. | |
| RT RealTime | https://files.constantcontact.com/971a6f79001/4f2519d8-bccc-42b9-8935-ba49b158798b.png | WORKFORCE DEVELOPMENT (e.g., investigator education & diversity) | https://realtime-eclinical.com/2025/02/10/from-zero-to-100-how-panoncology-trials-leveraged-technology-to-expand-access-and-diversity-in-clinical-research | From Zero to 100: How PanOncology Trials Leveraged Technology to Expand Access and Diversity in Clinical Research | Using RealTime’s integrated eClinical solutions, PanOncology has grown from 0 to 100 trials and expanded to five locations in only five years, with plans to continue increasing their locations throughout Puerto Rico to reach more underserved communities. | Using RealTime’s integrated eClinical solutions, PanOncology has grown from 0 to 100 trials and expanded to five locations in only five years, with plans to continue increasing their locations throughout Puerto Rico to reach more underserved communities. | |
| Subject Well | https://subjectwell.com/wp-content/uploads/sites/2/2024/11/site-logo.svg | WORKFORCE DEVELOPMENT (e.g., investigator education & diversity) | https://subjectwell.com/how-to-prepare-for-fda-mandated-clinical-diversity-action-plans-daps-2/ | Bridging the Gap: Why Diversity Action Plans Are Critical in Clinical Trials | With the FDA’s Diversity Action Plan taking effect in July 2025, clinical trials must move beyond acknowledgment to real action. Addressing past injustices and present biases is essential to building trust, ensuring inclusivity, and improving healthcare for all. | With the FDA’s Diversity Action Plan taking effect in July 2025, clinical trials must move beyond acknowledgment to real action. Addressing past injustices and present biases is essential to building trust, ensuring inclusivity, and improving healthcare for all. | |
| RT RealTime | https://files.constantcontact.com/971a6f79001/4f2519d8-bccc-42b9-8935-ba49b158798b.png | WORKFORCE DEVELOPMENT (e.g., investigator education & diversity) | https://realtime-eclinical.com/2025/02/10/from-zero-to-100-how-panoncology-trials-leveraged-technology-to-expand-access-and-diversity-in-clinical-research | From Zero to 100: How PanOncology Trials Leveraged Technology to Expand Access and Diversity in Clinical Research | PanOncology Trials was founded with the purpose of providing access to clinical trials for cancer patients in Puerto Rico, offering the possibility of improving their cancer treatment and quality of life. | PanOncology Trials was founded with the purpose of providing access to clinical trials for cancer patients in Puerto Rico, offering the possibility of improving their cancer treatment and quality of life. | |
| Applied Clinical Trials | https://files.constantcontact.com/971a6f79001/bbe2fb6d-70db-482d-9182-bd6051125ca6.png | WORKFORCE DEVELOPMENT (e.g., investigator education & diversity) | https://www.appliedclinicaltrialsonline.com/view/determining-effectiveness-decentralization-trials | Determining the Effectiveness of Decentralization Across Different Trials | In this video interview, Cameron Breze, product manager, Inovalon, highlights current trends with decentralization and how a dual approach can ensure flexibility across different therapeutic areas. | In this video interview, Cameron Breze, product manager, Inovalon, highlights current trends with decentralization and how a dual approach can ensure flexibility across different therapeutic areas. | |
| Applied Clinical Trials | https://files.constantcontact.com/971a6f79001/bbe2fb6d-70db-482d-9182-bd6051125ca6.png | WORKFORCE DEVELOPMENT (e.g., investigator education & diversity) | https://www.appliedclinicaltrialsonline.com/view/reaching-diverse-patient-populations-personalized-treatment | Enhancing Patient Engagement and Data Accuracy in Decentralized Trials | Andrew Mackinnon, executive GM, Medable, explains how the company ensures high patient participation and data accuracy in decentralized trials. | Andrew Mackinnon, executive GM, Medable, explains how the company ensures high patient participation and data accuracy in decentralized trials. | |
| Applied Clinical Trials | https://files.constantcontact.com/971a6f79001/bbe2fb6d-70db-482d-9182-bd6051125ca6.png | WORKFORCE DEVELOPMENT (e.g., investigator education & diversity) | https://www.appliedclinicaltrialsonline.com/view/reaching-diverse-patient-populations-personalized-treatment | Reaching Diverse Patient Populations With Personalized Treatment Methods | Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more. | Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more. | |
| Applied Clinical Trials | https://files.constantcontact.com/971a6f79001/bbe2fb6d-70db-482d-9182-bd6051125ca6.png | WORKFORCE DEVELOPMENT (e.g., investigator education & diversity) | https://www.appliedclinicaltrialsonline.com/view/modernizing-patient-recruitment | Modernizing Patient Recruitment | In this video interview, Cameron Breze, product manager, Inovalon, discusses current challenges with patient recruitment and how a combination of technology and manual effort can help improve efficiency. | In this video interview, Cameron Breze, product manager, Inovalon, discusses current challenges with patient recruitment and how a combination of technology and manual effort can help improve efficiency. | |
| Bristol Myers Squibb | https://s25.q4cdn.com/566753351/files/design/bms-rebrand-logo.svg | WORKFORCE DEVELOPMENT (e.g., investigator education & diversity) | https://www.roi-nj.com/2024/05/22/healthcare/bristol-myers-squibb-outlines-10-year-strategy-to-reach-patients-in-low-and-middle-income-countries/ | Bristol Myers Squibb Outlines 10-Year Strategy to Reach Patients in low- and Middle-Income Countries | Bristol Myers Squibb said Wednesday that it is creating a 10-year plan — ASPIRE, or Accessibility, Sustainability, Patient-centric, Impact, Responsibility and Equity — to expand access to its therapies to more than 200,000 patients in low- and middle-income countries by 2033. | Bristol Myers Squibb said it is creating a 10-year plan — ASPIRE, or Accessibility, Sustainability, Patient-centric, Impact, Responsibility and Equity — to expand access to its therapies to more than 200,000 patients in low- and middle-income countries by 2033. | |
| Bristol Myers Squibb | https://s25.q4cdn.com/566753351/files/design/bms-rebrand-logo.svg | WORKFORCE DEVELOPMENT (e.g., investigator education & diversity) | https://bionj.org/wp-content/uploads/2024/03/Bristol-Myers-Squibb-RD-diversity-plans-elements-.pdf | Study Diversity Plans Overview | Key elements of the study diversity plan. | Key elements of the study diversity plan. | |
| Bristol Myers Squibb | https://s25.q4cdn.com/566753351/files/design/bms-rebrand-logo.svg | WORKFORCE DEVELOPMENT (e.g., investigator education & diversity) | https://www.bms.com/about-us/responsibility/bristol-myers-squibb-foundation/our-focus-areas/diversity-in-clinical-trials.html | Diversity in Clinical Trials | The Robert A. Winn Diversity in Clinical Trials Award program, created by the Bristol Myers Squibb Foundation, develops clinical investigators who are racially and ethnically diverse or who are committed to increasing diversity in clinical trials, and exposes promising, underrepresented minority medical students to clinical research career pathways. | The Robert A. Winn Diversity in Clinical Trials Award program, created by the Bristol Myers Squibb Foundation, develops clinical investigators who are racially and ethnically diverse or who are committed to increasing diversity in clinical trials, and exposes promising, underrepresented minority medical students to clinical research career pathways. | |
| Bristol Myers Squibb | https://s25.q4cdn.com/566753351/files/design/bms-rebrand-logo.svg | WORKFORCE DEVELOPMENT (e.g., investigator education & diversity) | https://www.bms.com/life-and-science/news-and-perspectives/improving-diversity-and-inclusion-across-the-patient-experience.html | How BMS is Closing the Diversity Gap in Clinical Trials | Bristol Myers Squibb (BMS) is working hard to change that, and we’re gaining recognition as an industry leader in making clinical trials readily accessible to a broad range of patients around the world. | Bristol Myers Squibb (BMS) is working hard to change that, and we’re gaining recognition as an industry leader in making clinical trials readily accessible to a broad range of patients around the world. | |
| Otsuka | https://upload.wikimedia.org/wikipedia/commons/4/46/Otsuka_Holdings_logo.svg | WORKFORCE DEVELOPMENT (e.g., investigator education & diversity) | https://www.mhanational.org/ | Mental Health America (MHA) with support from Otsuka America Pharmaceuticals, Launches Equity Impact Zones (EIZ) Program | Mental Health America (MHA) with support from Otsuka America Pharmaceuticals, Inc. launched a new program called Equity Impact Zones (EIZ). The EIZ program will help New Jersey communities implement and sustain solutions to address mental health equity gaps. | Mental Health America (MHA) with support from Otsuka America Pharmaceuticals, Inc. launched a new program called Equity Impact Zones (EIZ). The EIZ program will help New Jersey communities implement and sustain solutions to address mental health equity gaps. | |
| Otsuka | https://upload.wikimedia.org/wikipedia/commons/4/46/Otsuka_Holdings_logo.svg | WORKFORCE DEVELOPMENT (e.g., investigator education & diversity) | https://njbia.org/otsuka-funds-grants-to-address-mental-health-inequities-in-nj-communities | Otsuka Funds Grants to Address Mental Health Inequities in NJ Communities | Mental Health America (MHA), with support from Otsuka America Pharmaceutical, have announced the recipients of the newly launched Equity Impact Zone (EIZ) grants, which are designed to address mental health equity gaps within local New Jersey communities. | Mental Health America (MHA), with support from Otsuka America Pharmaceutical, have announced the recipients of the newly launched Equity Impact Zone (EIZ) grants, which are designed to address mental health equity gaps within local New Jersey communities. | |
| BeiGene | https://bionj.org/wp-content/uploads/2024/02/BEIBENE.png | WORKFORCE DEVELOPMENT (e.g., investigator education & diversity) | https://reaganudall.org/news-and-events/announcements/regulatory-science-innovation-and-health-equity-fellowship | Regulatory Science, Innovation, and Health Equity Fellowship Established by Reagan-Udall Foundation for the FDA | The Reagan-Udall Foundation for the FDA is pleased to announce the launch of its Regulatory Science, Innovation, and Health Equity Fellowship Program. Increasing diversity in regulatory science serves to bring varied perspectives into the field and generate more meaningful results. | The Reagan-Udall Foundation for the FDA is pleased to announce the launch of its Regulatory Science, Innovation, and Health Equity Fellowship Program. Increasing diversity in regulatory science serves to bring varied perspectives into the field and generate more meaningful results. | |
| BeiGene | https://bionj.org/wp-content/uploads/2024/02/BEIBENE.png | WORKFORCE DEVELOPMENT (e.g., investigator education & diversity) | https://hkexir.beigene.com/news/the-max-foundation-beigene-and-the-beigene-foundation-announce-collaboration-to-advance-health-equity-by/b52d680b-1d1e-4bf3-8203-783c21441635/ | The Max Foundation, BeiGene, and the BeiGene Foundation Announce Collaboration to Advance Health Equity by Providing Access to BRUKINSA® for the Treatment of Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries | The Max Foundation and BeiGene announced a collaboration to provide access to BRUKINSA (zanubrutinib) for the treatment of adult patients with chronic lymphocytic leukemia (CLL) in 29 low- and middle-income countries over the next three years. | The Max Foundation and BeiGene announced a collaboration to provide access to BRUKINSA (zanubrutinib) for the treatment of adult patients with chronic lymphocytic leukemia (CLL) in 29 low- and middle-income countries over the next three years. | |
| TransCelerate | https://bionj.org/wp-content/uploads/2024/03/TransCelerate.png | WORKFORCE DEVELOPMENT (e.g., investigator education & diversity) | https://www.transceleratebiopharmainc.com/wp-content/uploads/2023/03/Diversity_FDA-Diversity-Plan-Early-Insights-and-Considerations_March-2023-2.pdf | Diversity of Participants in Clinical Trials | FDA Diversity Plan Early Insights and Considerations | FDA Diversity Plan Early Insights and Considerations | |
| Bristol Myers Squibb | https://s25.q4cdn.com/566753351/files/design/bms-rebrand-logo.svg | WORKFORCE DEVELOPMENT (e.g., investigator education & diversity) | https://www.bms.com/our-stories/science-and-innovation/learning-for-better-clinical-trials.html | AI and Multimodal Patient Data for Better, Faster Clinical Trials | As artificial intelligence (AI) programs achieve exponential gains in power and sophistication, Bristol Myers Squibb is exploring ways to leverage these technologies at many stages of the drug development process. In May 2022, BMS entered into a multi-year, strategic collaboration with Owkin, initially focusing on cardiovascular diseases. | As artificial intelligence (AI) programs achieve exponential gains in power and sophistication, Bristol Myers Squibb is exploring ways to leverage these technologies at many stages of the drug development process. In May 2022, BMS entered into a multi-year, strategic collaboration with Owkin, initially focusing on cardiovascular diseases. | |
| PHRMA | https://bionj.org/wp-content/uploads/2023/12/Phrma.png | WORKFORCE DEVELOPMENT (e.g., investigator education & diversity) | https://phrma.org/Equity/clinical-trial-diversity | Equitable Breakthroughs In Medicine Development | Equitable Breakthroughs in Medicine Development, a first-of-its-kind, cross-collaborative, community-based effort, seeks to tackle systemic challenges to clinical trial participation and share our findings broadly to help drive change. | Equitable Breakthroughs in Medicine Development, a first-of-its-kind, cross-collaborative, community-based effort, seeks to tackle systemic challenges to clinical trial participation and share our findings broadly to help drive change. | |
| Gilead | https://bionj.org/wp-content/uploads/2023/11/Gilead.png | WORKFORCE DEVELOPMENT (e.g., investigator education & diversity) | https://www.fiercebiotech.com/biotech/bristol-myers-squibb-foundation-unites-competition-effort-boost-diversity-among-trial | Gilead Unites with Bristol Myers Squibb Foundation to Boost Diversity Among Clinical Trial Investigators | Gilead will contribute $14 million over four years to the Bristol Myers Squibb Foundation’s career development program, which centers on elevating physicians of color. | Gilead will contribute $14 million over four years to the Bristol Myers Squibb Foundation’s career development program, which centers on elevating physicians of color. | |
| Gilead | https://bionj.org/wp-content/uploads/2023/11/Gilead.png | WORKFORCE DEVELOPMENT (e.g., investigator education & diversity) | https://www.gilead.com/news-and-press/press-room/press-releases/2024/2/gilead-announces-funding-initiative-to-support-hiv-prevention-antistigma-and-health-equity-efforts-for-black-cisgender-and-transgender-women-and-gir | Gilead Announces Funding Initiative to Support HIV Prevention, Anti-Stigma and Health Equity Efforts for Black Cisgender and Transgender Women and Girls in the U.S. | Gilead Sciences, Inc. announced it is providing a total of $12.6 million in grant funding to 19 organizations working to improve the HIV landscape for Black women and girls in the United States. | Gilead Sciences, Inc. announced it is providing a total of $12.6 million in grant funding to 19 organizations working to improve the HIV landscape for Black women and girls in the United States. | |
| Bristol Myers Squibb | https://s25.q4cdn.com/566753351/files/design/bms-rebrand-logo.svg | WORKFORCE DEVELOPMENT (e.g., investigator education & diversity) | https://news.bms.com/news/philanthropy/2023/The-Robert-A.-Winn-Diversity-in-Clinical-Trials-Award-Announces-Third-Group-of-Physicians-in-Program-to-Increase-Diversity-in-Clinical-Trials/default.aspx | Robert A. Winn Diversity in Clinical Trials Career Development Award | The Robert A. Winn Diversity in Clinical Trials Award Program aims to train, develop and mentor more than 308 clinical trialists and 308 medical students by 2027 who are diverse or who have a demonstrated commitment to clinical trial diversity. | The Robert A. Winn Diversity in Clinical Trials Award Program aims to train, develop and mentor more than 308 clinical trialists and 308 medical students by 2027 who are diverse or who have a demonstrated commitment to clinical trial diversity. | |
| Johnson & Johnson | https://bionj.org/wp-content/uploads/2023/10/JJ.png | WORKFORCE DEVELOPMENT (e.g., investigator education & diversity) | https://njbiz.com/johnson-johnson-launches-health-equity-innovation-challenge/ | Johnson & Johnson launches Health Equity Innovation Challenge | In a bid to address health disparities across the U.S., Johnson & Johnson is seeking changemakers to develop solutions to help close gaps in racial health and mortality in some of the country’s biggest cities. | In a bid to address health disparities across the U.S., Johnson & Johnson is seeking changemakers to develop solutions to help close gaps in racial health and mortality in some of the country’s biggest cities. | |
| Johnson & Johnson | https://bionj.org/wp-content/uploads/2023/10/JJ.png | WORKFORCE DEVELOPMENT (e.g., investigator education & diversity) | https://www.jnj.com/our-race-to-health-equity/dr-daphne-chan-is-helping-to-improve-clinical-trial-diversity-through-the-j-j-visible-study | Dr. Daphne Chan is helping to improve clinical trial diversity through the J&J VISIBLE study | Johnson & Johnson Our Race to Health Equity is profiling the people at the heart of the company who are working to make a more equitable world possible through its Health Equity Champion Spotlight series. | Johnson & Johnson Our Race to Health Equity is profiling the people at the heart of the company who are working to make a more equitable world possible through its Health Equity Champion Spotlight series. | |
| Johnson & Johnson | https://bionj.org/wp-content/uploads/2023/10/JJ.png | WORKFORCE DEVELOPMENT (e.g., investigator education & diversity) | https://www.jnj.com/media-center/press-releases/johnson-johnson-reaches-50-million-children-through-sight-for-kids-program | Johnson & Johnson Reaches 50 Million Children Through Sight For Kids Program | Johnson & Johnson announces that together with the Lions Clubs International Foundation (LCIF), Sight for Kids has provided comprehensive eye health services to more than 50 million students in underserved and low-income communities across North America, Africa, Asia and Europe. | Johnson & Johnson announces that together with the Lions Clubs International Foundation (LCIF), Sight for Kids has provided comprehensive eye health services to more than 50 million students in underserved and low-income communities across North America, Africa, Asia and Europe. | |
| Johnson & Johnson | https://bionj.org/wp-content/uploads/2023/10/JJ.png | WORKFORCE DEVELOPMENT (e.g., investigator education & diversity) | https://www.jnj.com/media-center/press-releases/johnson-johnson-expands-commitment-to-advance-health-equity-in-the-united-states | Johnson & Johnson Expands Commitment to Advance Health Equity in the United States | Johnson & Johnson supports more than 100 community-led organizations in marginalized communities to provide resources and tools to advance accessible, quality health care in the U.S. | Johnson & Johnson supports more than 100 community-led organizations in marginalized communities to provide resources and tools to advance accessible, quality health care in the U.S. | |
| My Health Can't Wait | https://bionj.org/wp-content/uploads/2023/09/my-health-cant-wait.png | WORKFORCE DEVELOPMENT (e.g., investigator education & diversity) | https://www.myhealthcantwait.com/ | My Health Can’t Wait | Johnson & Johnson presents My Health Can’t Wait is a community wellness initiative expanding access to vital health information and support for Patients and caregivers in communities of color. | Johnson & Johnson presents My Health Can’t Wait is a community wellness initiative expanding access to vital health information and support for Patients and caregivers in communities of color. | |
| Moderna | https://files.constantcontact.com/971a6f79001/94bdbaf7-a6cf-4501-a3d4-d6b6856ce76a.png | DATA TYPES (e.g., electronic health records) | https://www.modernatx.com/en-US/media-center/all-media/blogs/diseases-dont-discriminate-neither-should-clinical-research | Diversity & Inclusion in Clinical Trials: Building Moderna’s Capabilities | How Moderna is applying what was learned from its COVID-19 trial experience and how it is being applied to Moderna’s CMV Phase 3 study. | How Moderna is applying what was learned from its COVID-19 trial experience and how it is being applied to Moderna’s CMV Phase 3 study. | |
| Parexel | https://bionj.org/wp-content/uploads/2023/12/Parexel.png | DATA TYPES (e.g., electronic health records) | https://www.parexel.com/insights/report/patient-focused-drug-development/diversity-strategies/planning-early-diversity-helps-contain-costs-and-avoid-delays | Planning Early for Diversity Helps Contain costs and Avoid Delays | How creating a diversity plan early in development can make drug development more efficient. | How creating a diversity plan early in development can make drug development more efficient. | |
| Multi-Regional Clinical Trials | https://bionj.org/wp-content/uploads/2023/12/Multi-Regional-Clinical-Trials.png | DATA TYPES (e.g., electronic health records) | https://mrctcenter.org/diversity-in-clinical-research/tools/abd_toolkit/ | Accessibility by Design (AbD) Toolkit | The Accessibility by Design (AbD) in Clinical Research Toolkit is a comprehensive resource intended to be used by sponsors, institutions, investigators, ethics committees/IRBs, participants and Patient advocacy groups to support greater inclusion of people with disabilities in clinical research. | The Accessibility by Design (AbD) in Clinical Research Toolkit is a comprehensive resource intended to be used by sponsors, institutions, investigators, ethics committees/IRBs, participants and Patient advocacy groups to support greater inclusion of people with disabilities in clinical research. | |
| Boehringer Ingelheim | https://files.constantcontact.com/971a6f79001/01954ce0-d7f2-4967-b711-5ad1bd2259fa.png | DATA TYPES (e.g., electronic health records) | http://www.boehringer-ingelheim.com/sites/default/files/Prescription_Medicine/cns_prescription_medicine/DCT_Infographic.pdf | Decentralized Clinical Trials for Depression | Living with depression can mean that people find it hard to socialize or leave their home. Unfortunately, these challenges can make researching this complex condition even more difficult. Boehringer Ingelheim is working in partnership with Science37 to develop and run the first ever decentralized clinical trial for depression. | Living with depression can mean that people find it hard to socialize or leave their home. Unfortunately, these challenges can make researching this complex condition even more difficult. Boehringer Ingelheim is working in partnership with Science37 to develop and run the first ever decentralized clinical trial for depression. | |
| Ferring | https://files.constantcontact.com/971a6f79001/1b9156e3-a7ad-4187-ac6f-080c24c2325e.png | DATA TYPES (e.g., electronic health records) | https://www.ferring.com/science-innovation/research-areas/rmmh-equity-grants/ | Ferring Grants Program for Equity in Reproductive Medicine and Maternal Health | The Ferring Grants Program for Equity in Reproductive Medicine and Maternal Health aims to fund projects in basic and translational research, clinical research, epidemiology and prevention research and social science research. | The Ferring Grants Program for Equity in Reproductive Medicine and Maternal Health aims to fund projects in basic and translational research, clinical research, epidemiology and prevention research and social science research. | |
| Teva | https://files.constantcontact.com/971a6f79001/a9f4c006-cdef-475d-a6f3-8f6029e7bc67.png | DATA TYPES (e.g., electronic health records) | https://www.tevausa.com/news-and-media/article-pages/digital-equitable-health-alliance/ | Teva Joins Digital Health for Equitable Health Alliance [DHEH] | The coalition aims to address health disparities for low-income, minority and underserved populations through digital health. The DHEH champions policies and programs meant to increase equitable access to quality healthcare by building upon innovations in digital health, telemedicine, wearables, AI, machine learning and more to advance public health and well-being. | The coalition aims to address health disparities for low-income, minority and underserved populations through digital health. The DHEH champions policies and programs meant to increase equitable access to quality healthcare by building upon innovations in digital health, telemedicine, wearables, AI, machine learning and more to advance public health and well-being. | |
| Teva | https://files.constantcontact.com/971a6f79001/a9f4c006-cdef-475d-a6f3-8f6029e7bc67.png | DATA TYPES (e.g., electronic health records) | https://youtu.be/Rs13W24BmqQ | 3 Trends I'm Watching: Shoshi Friedman, Head of Global Clinical Operations Innovative Medicines | Clinical trials are essential for the development of safe and effective health care products. Learn more about the latest trends in the sector – from greater accessibility to increased diversity – and why they are essential for growth. | Clinical trials are essential for the development of safe and effective health care products. Learn more about the latest trends in the sector – from greater accessibility to increased diversity – and why they are essential for growth. | |
| Teva | https://files.constantcontact.com/971a6f79001/a9f4c006-cdef-475d-a6f3-8f6029e7bc67.png | DATA TYPES (e.g., electronic health records) | https://www.tevapharm.com/news-and-media/feature-stories/clinical-trial-diversity/ | Why Diversity in Clinical Trials is So Important | Teva investigates why it is vital for drug development and outlines its work in this space. | Teva investigates why it is vital for drug development and outlines its work in this space. | |
| Merck | https://files.constantcontact.com/971a6f79001/17a1b53f-11c9-4b3c-b7c7-46e6f9a2ab66.png | DATA TYPES (e.g., electronic health records) | https://blackdoctor.org/blackdoctor-merck-partnership/ | BlackDoctor.Org and Merck Announce Historic Partnership | BlackDoctor.org (BDO) and Merck are working together to improve Black American participation in clinical trials. Merck was the first to sign on to list its trials on BDO’s Clinical Trials Resource Center (CTRC). | BlackDoctor.org (BDO) and Merck are working together to improve Black American participation in clinical trials. Merck was the first to sign on to list its trials on BDO’s Clinical Trials Resource Center (CTRC). | |
| Merck | https://files.constantcontact.com/971a6f79001/17a1b53f-11c9-4b3c-b7c7-46e6f9a2ab66.png | DATA TYPES (e.g., electronic health records) | https://acrpnet.org/2023/01/12/merck-takes-action-to-address-clinical-research-workforce-challenges/ | Merck and ACRP Collaborations | The program aims to introduce the clinical research profession to high school and community college students by offering them ACRP’s Early Talent Training Program™, a comprehensive curriculum to prepare students for a career in the clinical research profession. | The program aims to introduce the clinical research profession to high school and community college students by offering them ACRP’s Early Talent Training Program™, a comprehensive curriculum to prepare students for a career in the clinical research profession. | |
| Merck | https://files.constantcontact.com/971a6f79001/17a1b53f-11c9-4b3c-b7c7-46e6f9a2ab66.png | DATA TYPES (e.g., electronic health records) | https://greenphire.com/news/greenphire-expands-agreement-with-merck-to-help-reduce-financial-and-travel-barriers-for-clinical-trial-participants-worldwide/ | Greenphire & Merck Help Reduce Financial and Travel Barriers for Clinical Trial Participants Worldwide | Greenphire’s ClinCard with rideshare integration is designed to help alleviate financial and logistical burdens on clinical trial participants. | Greenphire’s ClinCard with rideshare integration is designed to help alleviate financial and logistical burdens on clinical trial participants. | |
| ZZZZ Article | https://files.constantcontact.com/971a6f79001/c2293117-5a46-42f5-adcd-d11e94cd512d.png | WORKFORCE DEVELOPMENT (e.g., investigator education & diversity) | https://pharmanewsintel.com/features/clinical-trial-diversity-inclusion-key-to-advancing-health-equity | Advancing Health Equity with Clinical Trial Diversity: Key Strategies | Article: Although research has consistently displayed a lack of participant diversity in clinical trials, improving clinical trial diversity is a key strategy for advancing health equity. | Article: Although research has consistently displayed a lack of participant diversity in clinical trials, improving clinical trial diversity is a key strategy for advancing health equity. | |
| ZZZZ Article | https://files.constantcontact.com/971a6f79001/c2293117-5a46-42f5-adcd-d11e94cd512d.png | WORKFORCE DEVELOPMENT (e.g., investigator education & diversity) | https://ascopubs.org/doi/full/10.1200/EDBK_389838 | Equitable Access to Clinical Trials: How Do We Achieve It? | Study populations for cancer clinical trials do not match the composition of targeted populations for cancer therapies. A variety of changes to clinical trial requirements can improve the accrual of patients from underserved populations to cancer clinical trials. | Study populations for cancer clinical trials do not match the composition of targeted populations for cancer therapies. A variety of changes to clinical trial requirements can improve the accrual of patients from underserved populations to cancer clinical trials. | |
| ZZZZ Article | https://files.constantcontact.com/971a6f79001/c2293117-5a46-42f5-adcd-d11e94cd512d.png | WORKFORCE DEVELOPMENT (e.g., investigator education & diversity) | https://news.bloomberglaw.com/pharma-and-life-sciences/diversity-in-clinical-trials-at-fda-gets-a-boost-from-new-law | Diversity in Clinical Trials at FDA Gets a Boost From New Law | The 2023 omnibus spending bill (Public Law 117-328) requires diversity action plans for the clinical trials used by the Food and Drug Administration to decide whether drugs are safe and effective. | The 2023 omnibus spending bill (Public Law 117-328) requires diversity action plans for the clinical trials used by the Food and Drug Administration to decide whether drugs are safe and effective. | |
| ZZZZ Webinar | https://bionj.org/wp-content/uploads/2024/01/Webinar.png | WORKFORCE DEVELOPMENT (e.g., investigator education & diversity) | https://bionj.org/bionjs-health-equity-in-clinical-trials-best-practices-webinar-examples-from-which-to-learn-opportunities-for-collaboration/ | BioNJ’s Health Equity in Clinical Trials Best Practices Webinar Series: Examples from Which to Learn & Opportunities for Collaboration | We are pleased to announce the first webinar in BioNJ’s Health Equity in Clinical Trials Best Practices Webinar Series: Examples from Which to Learn & Opportunities for Collaboration | We are pleased to announce the first webinar in BioNJ’s Health Equity in Clinical Trials Best Practices Webinar Series: Examples from Which to Learn & Opportunities for Collaboration | |
| ZZZZ Webinar | https://bionj.org/wp-content/uploads/2024/01/Webinar.png | WORKFORCE DEVELOPMENT (e.g., investigator education & diversity) | https://bionj.org/designing-trials-to-broaden-reach-and-expand-diversity-video/ | BioNJ’s Health Equity in Clinical Trials Best Practices Webinar: Designing Trials to Broaden Reach and Expand Diversity | We are pleased to announce the second webinar in BioNJ’s Health Equity in Clinical Trials Best Practices Webinar Series: Broaden Reach and Expand Diversity in Clinical Trials. | We are pleased to announce the second webinar in BioNJ’s Health Equity in Clinical Trials Best Practices Webinar Series: Designing Trials to Broaden Reach and Expand Diversity | |
| Yale | https://upload.wikimedia.org/wikipedia/commons/thumb/f/f0/Yale_Cancer_Center.svg/346px-Yale_Cancer_Center.svg.png | PATIENT RECRUITMENT, ENGAGEMENT & COMMUNITY OUTREACH | https://www.yalecancercenter.org/news-article/support-secured-for-yale-cancer-center-consortium-to-advance-equity-in-early-phase-clinical-trials/ | Yale Cancer Center Consortium to Advance Equity in Early Phase Clinical Trials | The intent of the Consortium is to help increase access to early phase cancer clinical trials for Patients who would otherwise not have the ability to be treated with novel investigational therapeutic interventions. | The intent of the Consortium is to help increase access to early phase cancer clinical trials for Patients who would otherwise not have the ability to be treated with novel investigational therapeutic interventions. | |
| ZZZZ Article | https://files.constantcontact.com/971a6f79001/c2293117-5a46-42f5-adcd-d11e94cd512d.png | SITE SELECTION & EXPANSION | https://www.pewresearch.org/short-reads/2023/02/10/key-facts-about-black-americans/ | Site Selection & Expansion | Census-based diversity calculations include different ethnic group: Hispanic; White; Black or African American; Asian; Native Hawaiian and Other Pacific Islanders. Some sites should be selected in regions where these groups reside. | Census-based diversity calculations include different ethnic group: Hispanic; White; Black or African American; Asian; Native Hawaiian and Other Pacific Islanders. Some sites should be selected in regions where these groups reside. | |
| Sanofi | https://files.constantcontact.com/971a6f79001/3d6bca01-ddb0-4243-a7a9-f4e9df3a383a.png | PATIENT RECRUITMENT, ENGAGEMENT & COMMUNITY OUTREACH | https://www.sanofi.com/en/magazine/our-science/building-a-more-equitable-future-through-inclusive-clinical-trials | Building a More Equitable Future through Inclusive Clinical Trials | To reach diverse Patient groups, we need to engage with new physicians, new trial sites and essentially new communities. | To reach diverse Patient groups, we need to engage with new physicians, new trial sites and essentially new communities. | |
| Sanofi | https://files.constantcontact.com/971a6f79001/3d6bca01-ddb0-4243-a7a9-f4e9df3a383a.png | PATIENT RECRUITMENT, ENGAGEMENT & COMMUNITY OUTREACH | https://www.sanofi.us/en/sanofi-today/social-impact/are-you-reflected-in-clinical-trials | Are You Reflected in Clinical Trials? | Trust is the cornerstone of healthcare and clinical research, yet many marginalized communities remain underrepresented and underserved. Insights from Sanofi’s A Million Conversations initiative, along with leading expert voices, underscore the trust gap that exists in healthcare – a gap shaped by historical inequities and negative experiences. Closing the gap is essential for improving health outcomes for all. | Trust is the cornerstone of healthcare and clinical research, yet many marginalized communities remain underrepresented and underserved. Insights from Sanofi’s A Million Conversations initiative, along with leading expert voices, underscore the trust gap that exists in healthcare – a gap shaped by historical inequities and negative experiences. Closing the gap is essential for improving health outcomes for all. | |
| Sanofi | https://files.constantcontact.com/971a6f79001/3d6bca01-ddb0-4243-a7a9-f4e9df3a383a.png | PATIENT RECRUITMENT, ENGAGEMENT & COMMUNITY OUTREACH | https://www.sanofi.us/en/our-company/social-impact/diversity-equity-and-inclusion-in-and-beyond-the-workplace/a-million-conversations-addressing-disparities-in-healthcare | A Million Conversations | A Million Conversations, Sanofi’s global initiative, works to bridge the healthcare trust gap within marginalized communities across the U.S. | A Million Conversations, Sanofi’s global initiative, works to bridge the healthcare trust gap within marginalized communities across the U.S. | |
| Rutgers Univeristy | https://ifh.rutgers.edu/wp-content/themes/RUwebsite/img/IFH_RutgersUniversity.png | PATIENT RECRUITMENT, ENGAGEMENT & COMMUNITY OUTREACH | https://cohort.rutgers.edu/en | The New Jersey Population Health Cohort Study | The NJ Population Health Cohort Study was launched in 2022 to improve understanding of how life events and stress affect health, particularly within historically disadvantaged groups, multigenerational families and immigrant groups. The overarching goal of the study is to offer practical, actionable information for improving population health, well-being and health equity. | The New Jersey Population Health Cohort Study was launched in 2022 to improve understanding of how life events and stress affect health, particularly within historically disadvantaged groups, multigenerational families, and immigrant groups. The overarching goal of the study is to offer practical, actionable information for improving population health, well-being and health equity in New Jersey and beyond. | |
| Rutgers Cancer Institute | https://files.constantcontact.com/971a6f79001/77f2d3f2-a5c0-4fec-88a4-31fe2a22b0ea.png | PATIENT RECRUITMENT, ENGAGEMENT & COMMUNITY OUTREACH | https://issuu.com/rutgerscancerhealthequity/docs/rutgers_checoe_impactreport_2021_execsummary_r8 | Cancer Health Equity Center of Excellence 2021 Executive Summary | Advancing the achievement of equitable access, improved health care quality and better outcomes across the cancer continuum. | Advancing the achievement of equitable access, improved health care quality and better outcomes across the cancer continuum. | |
| Rutgers Cancer Institute | https://files.constantcontact.com/971a6f79001/77f2d3f2-a5c0-4fec-88a4-31fe2a22b0ea.png | PATIENT RECRUITMENT, ENGAGEMENT & COMMUNITY OUTREACH | https://www.cinj.org/outreach/cancer-health-equity-center-excellence | Cancer Health Equity Center of Excellence | The Cancer Health Equity Center of Excellence is a formal partnership between the Rutgers School of Public Health and the Rutgers Cancer Institute of NJ, which will serve as a catalyst for training and education, research, community engagement and public policy advocacy surrounding cancer health equity in one of the nation’s most ethnically and racially diverse states. | The Cancer Health Equity Center of Excellence is a formal partnership between the Rutgers School of Public Health and the Rutgers Cancer Institute of NJ, which will serve as a catalyst for training and education, research, community engagement and public policy advocacy surrounding cancer health equity in one of the nation’s most ethnically and racially diverse states. | |
| Regeneron | https://files.constantcontact.com/971a6f79001/82ef148d-2910-4bec-81a7-c3c68ff81e9d.png | PATIENT RECRUITMENT, ENGAGEMENT & COMMUNITY OUTREACH | https://www.regeneron.com/downloads/dei-impact-report-2022.pdf | Mexico City Prospective Study (pg. 22) | The MCPS, a study by RGC in collaboration with the Universidad Nacional Autónoma de México and Oxford University, is the largest genomic research study in a Hispanic and LatinX population to date. | The MCPS, a study by RGC in collaboration with the Universidad Nacional Autónoma de México and Oxford University, is the largest genomic research study in a Hispanic and LatinX population to date. | |
| PTC Therapeutics | https://files.constantcontact.com/971a6f79001/36334469-9b79-4c59-bbfc-38633f6dfdad.png | TRIAL SPONSOR (e.g., influence study & protocol design) | https://files.constantcontact.com/971a6f79001/99f24e7e-097a-4f65-bfa1-64542301105b.pdf | PTC Therapeutics Biomarker Working Group | The purpose of the PTC Biomarker Working Group is to develop a global, comprehensive biomarker strategy consistent with our mission to provide access to best-in-class treatments for rare disease Patients who have little to no treatment options. | The purpose of the PTC Biomarker Working Group is to develop a global, comprehensive biomarker strategy consistent with our mission to provide access to best-in-class treatments for rare disease Patients who have little to no treatment options. | |
| Pfizer | https://files.constantcontact.com/971a6f79001/6d12ec95-8545-49ca-b6cc-617b877a605a.png | WORKFORCE DEVELOPMENT (e.g., investigator education & diversity) | https://www.pfizer.com/sites/default/files/investors/financial_reports/annual_reports/2022/story/ensuring-diversity-in-clinical-trials-to-develop-breakthroughs-for-all/ | Health Equity, Advocacy, and Leadership (HEAL) | A partnership with the Tigerlily Foundation to advance education around clinical trials for Black women with breast cancer. | A partnership with the Tigerlily Foundation to advance education around clinical trials for Black women with breast cancer. | |
| Pfizer | https://files.constantcontact.com/971a6f79001/6d12ec95-8545-49ca-b6cc-617b877a605a.png | WORKFORCE DEVELOPMENT (e.g., investigator education & diversity) | https://www.sciencedirect.com/science/article/pii/S1551714423001076 | A Framework for Setting Enrollment Goals to Ensure Participant Diversity in Sponsored Clinical Trials in the United States | The aim of this study was to establish a transparent and reproducible process for setting trial diversity enrollment goals informed by the disease epidemiology. | The aim of this study was to establish a transparent and reproducible process for setting trial diversity enrollment goals informed by the disease epidemiology. | |
| Pfizer | https://files.constantcontact.com/971a6f79001/6d12ec95-8545-49ca-b6cc-617b877a605a.png | WORKFORCE DEVELOPMENT (e.g., investigator education & diversity) | https://www.businesswire.com/news/home/20240202234166/en/Breaking-Barriers-in-Cancer-Care-The-American-Cancer-Society-and-Pfizer-Announce-a-15-Million-Three-Year-Initiative-to-Bridge-the-Gap-in-Cancer-Care-Disparities | Breaking Barriers in Cancer Care: The American Cancer Society and Pfizer Announce a $15 Million, Three-Year Initiative to Bridge the Gap in Cancer Care Disparities | The initiative, “Change the Odds: Uniting to Improve Cancer Outcomes” aims to enhance awareness of and access to cancer screening, clinical trials and support in medically underrepresented communities across the United States. | The initiative, “Change the Odds: Uniting to Improve Cancer Outcomes” aims to enhance awareness of and access to cancer screening, clinical trials and support in medically underrepresented communities across the United States. | |
| Pfizer | https://files.constantcontact.com/971a6f79001/6d12ec95-8545-49ca-b6cc-617b877a605a.png | WORKFORCE DEVELOPMENT (e.g., investigator education & diversity) | https://www.pfizer.com/news/announcements/closing-cancer-care-gap-world-cancer-day-and-beyond | Closing the Cancer Care Gap: World Cancer Day and Beyond | Every two seconds, someone in the world is diagnosed with cancer.1 It’s a disease that knows no borders, doesn’t distinguish between race or religion, and pays no mind to whether a person is rich or poor. The great equalizer, it touches every corner of the globe. | Every two seconds, someone in the world is diagnosed with cancer.1 It’s a disease that knows no borders, doesn’t distinguish between race or religion, and pays no mind to whether a person is rich or poor. The great equalizer, it touches every corner of the globe. | |
| Pfizer | https://files.constantcontact.com/971a6f79001/6d12ec95-8545-49ca-b6cc-617b877a605a.png | WORKFORCE DEVELOPMENT (e.g., investigator education & diversity) | https://www.worldcancerday.org/about/2022-2024-world-cancer-day-campaign | World Cancer Day 2022-2024 theme: Close the Care Gap | World Cancer Day 2024 the theme is still "Close the Care Gap". The campaign is all about understanding and recognising the inequities in cancer care around the globe. This World Cancer Day, we recognise the power of working together. | World Cancer Day 2024 the theme is still "Close the Care Gap". The campaign is all about understanding and recognising the inequities in cancer care around the globe. This World Cancer Day, we recognise the power of working together. | |
| Pfizer | https://files.constantcontact.com/971a6f79001/6d12ec95-8545-49ca-b6cc-617b877a605a.png | WORKFORCE DEVELOPMENT (e.g., investigator education & diversity) | https://www.cancer.org/about-us/our-partners/pfizer.html | The American Cancer Society and Pfizer: Breaking Barriers in Cancer Care Disparities | The American Cancer Society (ACS) and Pfizer launched on February 5th, “Change the Odds: Uniting to Improve Cancer OutcomesTM,” a three-year initiative to address disparities in cancer care. Through $15 million in funding from Pfizer, the initiative aims to improve health outcomes in medically underrepresented communities across the United States by enhancing awareness of and access to cancer screenings, clinical trial opportunities, patient support and comprehensive navigation. | The American Cancer Society (ACS) and Pfizer launched on February 5th, “Change the Odds: Uniting to Improve Cancer OutcomesTM,” a three-year initiative to address disparities in cancer care. Through $15 million in funding from Pfizer, the initiative aims to improve health outcomes in medically underrepresented communities across the United States by enhancing awareness of and access to cancer screenings, clinical trial opportunities, patient support and comprehensive navigation. | |
| Pfizer | https://files.constantcontact.com/971a6f79001/6d12ec95-8545-49ca-b6cc-617b877a605a.png | WORKFORCE DEVELOPMENT (e.g., investigator education & diversity) | https://cdn.pfizer.com/pfizercom/Pfizer_Racial_Equity_Assessment_Report_031424.pdf | Diversity, Equity and Inclusion | Diversity, Equity and Inclusion | This report reflects the views of the assessment team, which relied on data and representations provided by Pfizer's management, employees, and third parties, some of which the assessment team was not able to confirm independently. | |
| Pfizer | https://files.constantcontact.com/971a6f79001/6d12ec95-8545-49ca-b6cc-617b877a605a.png | WORKFORCE DEVELOPMENT (e.g., investigator education & diversity) | https://cdn.pfizer.com/pfizercom/Pfizer_Racial_Equity_Assessment_Report_031424.pdf | Diversity, Equity and Inclusion | This report reflects the views of the assessment team, which relied on data and representations provided by Pfizer's management, employees, and third parties, some of which the assessment team was not able to confirm independently. | This report reflects the views of the assessment team, which relied on data and representations provided by Pfizer's management, employees, and third parties, some of which the assessment team was not able to confirm independently. | |
| Novo Nordisk | https://www.novartis.com/us-en/themes/custom/nvs_arctic/logo.svg | WORKFORCE DEVELOPMENT (e.g., investigator education & diversity) | https://www.novartis.com/us-en/esg/beacon-hope | Beacon of Hope | Novartis & the Novartis US Foundation take a major step forward to address the root causes of disparities in health and education by launching Beacon of Hope, an innovative ten-year collaboration with 26 Historically Black Colleges and Universities. | Novartis & the Novartis US Foundation take a major step forward to address the root causes of disparities in health and education by launching Beacon of Hope, an innovative ten-year collaboration with 26 Historically Black Colleges and Universities. | |
| Multi-Regional Clinical Trials | https://bionj.org/wp-content/uploads/2023/09/logo-mrct-center.png | WORKFORCE DEVELOPMENT (e.g., investigator education & diversity) | https://mrctcenter.org/diversity-in-clinical-research/guidance/guidance-document/ | Achieving Diversity, Inclusion, and Equity in Clinical Research | This Guidance Document aims to clarify the importance of, advance the goals of, and provide practical and actionable ways to improve diverse representation of participants in clinical research. | This Guidance Document aims to clarify the importance of, advance the goals of, and provide practical and actionable ways to improve diverse representation of participants in clinical research. | |
| Multi-Regional Clinical Trials | https://bionj.org/wp-content/uploads/2023/09/logo-mrct-center.png | WORKFORCE DEVELOPMENT (e.g., investigator education & diversity) | https://mrctcenter.org/diversity-in-clinical-research/download/1531/ | Case Study: Multiple Sclerosis Research Mythbusting Series | How Accelerated Cure Project (ACP) and the Multiple Sclerosis Association of America (MSAA) collaborated to further diverse clinical trial participation. | How Accelerated Cure Project (ACP) and the Multiple Sclerosis Association of America (MSAA) collaborated to further diverse clinical trial participation. | |
| Multi-Regional Clinical Trials | https://bionj.org/wp-content/uploads/2023/09/logo-mrct-center.png | WORKFORCE DEVELOPMENT (e.g., investigator education & diversity) | https://mrctcenter.org/diversity-in-clinical-research/download/1529/ | Case Study: Achieving and Exceeding Clinical Trial Participant Diversity Targets | How Merck increased clinical trial diversity using Customized Tools, Applications and a Dynamic Enrollment Tracker. | How Merck increased clinical trial diversity using Customized Tools, Applications and a Dynamic Enrollment Tracker. | |
| Novo Nordisk | https://files.constantcontact.com/971a6f79001/cf3bfcb6-ad0f-45cd-bb27-5c306f9161bb.png | PATIENT RECRUITMENT, ENGAGEMENT & COMMUNITY OUTREACH | https://www.novonordisk.com/content/dam/nncorp/global/en/sustainable-business/pdfs/driving-change-for-patiens-and-society.pdf | Report: Clinical Trials Driving Change for Patients and Society | This report examines how Novo Nordisk’s clinical trials also generate value and drive change by nurturing innovation, prioritizing Patient needs and advocating for sustainability. | This report examines how Novo Nordisk’s clinical trials also generate value and drive change by nurturing innovation, prioritizing Patient needs and advocating for sustainability. | |
| Novo Nordisk | https://files.constantcontact.com/971a6f79001/94b944b7-1880-42d9-b63d-e035b7fa8193.png | SCREENING PROCESSES (e.g., decentralized trial technologies) | https://www.otsuka-us.com/node/676 | Use of Spencer® Smart Hub in Clinical Trials and Commercial Applications | Leveraging technology to improve diversity and inclusion in clinical research. | Leveraging technology to improve diversity and inclusion in clinical research. | |
| Pfizer | https://files.constantcontact.com/971a6f79001/6d12ec95-8545-49ca-b6cc-617b877a605a.png | PATIENT RECRUITMENT, ENGAGEMENT & COMMUNITY OUTREACH | https://www.sciencedirect.com/science/article/pii/S1551714421001579 | Demographic Diversity of Participants in Pfizer Sponsored Clinical Trials in the United States | To gain an understanding on the disparity of minority representation in our own studies, we published a landmark, 10-year retrospective analysis (taking data from 2011–2020) of the ethnic, racial, age and gender diversity in our clinical trials. | To gain an understanding on the disparity of minority representation in our own studies, we published a landmark, 10-year retrospective analysis (taking data from 2011–2020) of the ethnic, racial, age and gender diversity in our clinical trials. | |
| Pfizer | https://files.constantcontact.com/971a6f79001/6d12ec95-8545-49ca-b6cc-617b877a605a.png | PATIENT RECRUITMENT, ENGAGEMENT & COMMUNITY OUTREACH | https://cdn.pfizer.com/pfizercom/Pfizer_APR_WhitePaper_080921.pdf | Pfizer Oncology Patient Centricity Ecosystem | To provide learnings and best practice suggestions for others seeking to pursue similar efforts, this report provides a detailed overview of how Pfizer and a network of cancer patient advocacy leaders collectively designed processes and built this foundational infrastructure – an ecosystem – for partnering to advance patient centricity. | To provide learnings and best practice suggestions for others seeking to pursue similar efforts, this report provides a detailed overview of how Pfizer and a network of cancer patient advocacy leaders collectively designed processes and built this foundational infrastructure – an ecosystem – for partnering to advance patient centricity. | |
| Novartis | https://files.constantcontact.com/971a6f79001/095c85a1-7c5c-4126-b872-afa334595bb7.png | PATIENT RECRUITMENT, ENGAGEMENT & COMMUNITY OUTREACH | https://www.researchmatch.org/ | ResearchMatch | ResearchMatch is a nonprofit program funded by the National Institutes of Health (NIH). It helps to connect people interested in research studies with researchers from top medical centers across the U.S. | ResearchMatch is a nonprofit program funded by the National Institutes of Health (NIH). It helps to connect people interested in research studies with researchers from top medical centers across the U.S. | |
| National Medical Fellowships | https://files.constantcontact.com/971a6f79001/f7c3b7ae-df73-43af-b406-d666922e483a.png | WORKFORCE DEVELOPMENT (e.g., investigator education & diversity) | https://nmfonline.org/scholarships-programs/diversity-in-research/clinical-trials-research/ | National Medical Fellowships Diversity in Clinical Trials Research Program (NMF Dctr) | The NMF Dctr seeks to increase the number of clinicians underrepresented in medicine who serve as Principal Investigators, as part of the strategy to increase Patient diversity in clinical trials. | The NMF Dctr seeks to increase the number of clinicians underrepresented in medicine who serve as Principal Investigators, as part of the strategy to increase Patient diversity in clinical trials. | |
| Milken Institute | https://milkeninstitute.org/themes/custom/milken/logo.svg | PATIENT RECRUITMENT, ENGAGEMENT & COMMUNITY OUTREACH | https://milkeninstitute.org/sites/default/files/2023-04/MappingtheJourneyBuildingaMutualUnderstandingforDiversityandEquityinBiomedicalResearchandClinicalTrials_0.pdf | MAPPING THE JOURNEY: Building a Mutual Understanding for Health Equity in Clinical Research | The Milken Institute is a nonprofit, nonpartisan think tank focused on accelerating measurable progress on the path to a meaningful life. "MAPPING THE JOURNEY: Building a Mutual Understanding for Health Equity in Clinical Research" was published April 2023. | The Milken Institute is a nonprofit, nonpartisan think tank focused on accelerating measurable progress on the path to a meaningful life. "MAPPING THE JOURNEY: Building a Mutual Understanding for Health Equity in Clinical Research" was published April 2023. | |
| Milken Institute | https://milkeninstitute.org/themes/custom/milken/logo.svg | PATIENT RECRUITMENT, ENGAGEMENT & COMMUNITY OUTREACH | https://milkeninstitute.org/report/clinical-trials-achieving-diversity | Achieving Health Equity: A Multi-Stakeholder Action Plan to Address Diversity across the Clinical Trials Enterprise and the Biomedical Research Ecosystem | To drive needed actions forward in a structured and impactful way, FasterCures convened an advisory working group of experts from academia, industry, policy groups, patient advocacy, and disease-specific patient organizations to dive deeper into these issues. | To drive needed actions forward in a structured and impactful way, FasterCures convened an advisory working group of experts from academia, industry, policy groups, patient advocacy, and disease-specific patient organizations to dive deeper into these issues. | |
| Merck | https://www.merck.com/wp-content/themes/mhh-merck-mco-theme/images/site-logo.svg | WORKFORCE DEVELOPMENT (e.g., investigator education & diversity) | https://www.merck.com/stories/podcast-how-to-bridge-diversity-gaps-in-cancer-clinical-trials/ | Podcast: How to Bridge Diversity Gaps in Cancer Clinical Trials | Luther Clark talks with Lazarex Cancer Foundation's Dana Dornsife and Marya Shegog about increasing access among historically underrepresented communities. | Luther Clark talks with Lazarex Cancer Foundation's Dana Dornsife and Marya Shegog about increasing access among historically underrepresented communities. | |
| Merck | https://www.merck.com/wp-content/themes/mhh-merck-mco-theme/images/site-logo.svg | WORKFORCE DEVELOPMENT (e.g., investigator education & diversity) | https://www.merck.com/stories/how-we-foster-innovation-through-our-diverse-workforce/ | Inspiring Innovation Through Diversity and Inclusion | Beyond clinical trials, we know commitment to diversity in research starts within, from the people we hire to those we choose as partners. | Beyond clinical trials, we know commitment to diversity in research starts within, from the people we hire to those we choose as partners. | |
| Merck | https://www.merck.com/wp-content/themes/mhh-merck-mco-theme/images/site-logo.svg | WORKFORCE DEVELOPMENT (e.g., investigator education & diversity) | https://www.merck.com/stories/were-training-more-minority-investigators-to-help-improve-diversity-in-clinical-trials/ | We’re Training More Minority Investigators to Help Improve Diversity in Clinical Trials | Merck's sponsorship of the National Medical Fellowships’ Diversity in Clinical Trials Research program aims to support and train minority physicians to become principal investigators (PIs) in clinical trials. | Merck's sponsorship of the National Medical Fellowships’ Diversity in Clinical Trials Research program aims to support and train minority physicians to become principal investigators (PIs) in clinical trials. | |
| Merck | https://www.merck.com/wp-content/themes/mhh-merck-mco-theme/images/site-logo.svg | WORKFORCE DEVELOPMENT (e.g., investigator education & diversity) | https://www.merck.com/stories/podcast-a-candid-conversation-about-diversity-in-clinical-trials/ | Diversity in Clinical Trials PodCast May 2024 | Podcast: A candid conversation about diversity in clinical trials. Hear a patient and a doctor share why they want more people involved in medical studies. | Podcast: A candid conversation about diversity in clinical trials. Hear a patient and a doctor share why they want more people involved in medical studies. | |
| Medidata | https://files.constantcontact.com/971a6f79001/9aa65425-4b8a-4972-8407-85242f122aa5.png | PATIENT RECRUITMENT, ENGAGEMENT & COMMUNITY OUTREACH | https://www.medidata.com/en/the-state-of-black-participation-in-clinical-trials-white-paper/ | The State of Black Participation in Clinical Trials: Evaluating Enrollment Trends | This analysis covers 972,773 trial participants, 4,003 global trials and various levels of data granularity including global, US, TA and site level analysis. This latest analysis uncovers variation previously masked by aggregate enrollment estimates of Black enrollment in clinical trials. | This analysis covers 972,773 trial participants, 4,003 global trials and various levels of data granularity including global, US, TA and site level analysis. This latest analysis uncovers variation previously masked by aggregate enrollment estimates of Black enrollment in clinical trials. | |
| Medidata | https://files.constantcontact.com/971a6f79001/9aa65425-4b8a-4972-8407-85242f122aa5.png | PATIENT RECRUITMENT, ENGAGEMENT & COMMUNITY OUTREACH | https://www.medidata.com/en/webinar-walking-the-talk/ | Walking the Talk: Webinar | Industry thought leaders from Medidata, AbbVie, Emerson Clinical Research and Memorial Sloan Kettering Cancer Center as they share best practices on how to transform trials design, reduce Patient burden and build sustainable community relationships. | Industry thought leaders from Medidata, AbbVie, Emerson Clinical Research and Memorial Sloan Kettering Cancer Center as they share best practices on how to transform trials design, reduce Patient burden and build sustainable community relationships. | |
| Medidata | https://files.constantcontact.com/971a6f79001/9aa65425-4b8a-4972-8407-85242f122aa5.png | PATIENT RECRUITMENT, ENGAGEMENT & COMMUNITY OUTREACH | https://www.medidata.com/wp-content/uploads/2022/02/FAQs-to-Guide-Your-DCT-Strategy-Jan-22.pdf | What Are Decentralized Clinical Trials? | Find the most frequently asked questions and answers on what decentralized clinical trials mean. | Find the most frequently asked questions and answers on what decentralized clinical trials mean. | |
| Jannsen | https://files.constantcontact.com/971a6f79001/683fc9c1-3815-4b49-837b-044bc7f7cb4c.png | PATIENT RECRUITMENT, ENGAGEMENT & COMMUNITY OUTREACH | https://www.researchincludesme.com/ | Research Includes Me | Janssen’s Research Includes Me initiative seeks to identify needs, build trust and break down barriers to access, with a particular focus on traditionally underrepresented communities. Research Includes Me provides educational materials, hosts community events and connects Patients to clinical research opportunities. | Janssen’s Research Includes Me initiative seeks to identify needs, build trust and break down barriers to access, with a particular focus on traditionally underrepresented communities. Research Includes Me provides educational materials, hosts community events and connects Patients to clinical research opportunities. | |
| Jannsen | https://files.constantcontact.com/971a6f79001/683fc9c1-3815-4b49-837b-044bc7f7cb4c.png | PATIENT RECRUITMENT, ENGAGEMENT & COMMUNITY OUTREACH | https://standuptocancer.org/press/stand-up-to-cancer-announces-5-million-sponsorship-from-janssen-in-support-of-initiative-to-improve-health-equity-in-clinical-trials/#:~:text=A%20%245%20million%20sponsorship%20from%20Janssen%20will%20support,as%20well%20as%20patients%20in%20medically%20underserved%20communities. | Stand Up To Cancer | Janssen Oncology sponsored a $5 million grant with Stand Up to Cancer, a nonprofit organization supporting cancer research, to support the development of initiatives focused on increasing diversity in early phase cancer clinical trials. | Janssen Oncology sponsored a $5 million grant with Stand Up to Cancer, a nonprofit organization supporting cancer research, to support the development of initiatives focused on increasing diversity in early phase cancer clinical trials. | |
| Jannsen | https://files.constantcontact.com/971a6f79001/683fc9c1-3815-4b49-837b-044bc7f7cb4c.png | PATIENT RECRUITMENT, ENGAGEMENT & COMMUNITY OUTREACH | https://smdp.icpdprograms.org/project/janssen_sodep/ | Scholars of Oncology Diversity Engagement Program (Janssen SODEP) | Janssen's SODEP program aims to build relationships with ethnically diverse students and post-doctoral researchers to contribute to shaping their career and bring visibility to our job opportunities by providing exposure and mentorship, with the goal of possible job placement. | Janssen's SODEP program aims to build relationships with ethnically diverse students and post-doctoral researchers to contribute to shaping their career and bring visibility to our job opportunities by providing exposure and mentorship, with the goal of possible job placement. | |
| Jannsen | https://files.constantcontact.com/971a6f79001/683fc9c1-3815-4b49-837b-044bc7f7cb4c.png | PATIENT RECRUITMENT, ENGAGEMENT & COMMUNITY OUTREACH | https://skinofcolorsociety.org/?s=Diversity+in+Clinical+Research+Mentoring+Program | Janssen Partnership with the National Medical Association (NMA) Project IMPACT 2.0 Coalition and Skin of Color Society (SOCS) | This partnership aims to bridge the clinical trial experience gap. By facilitating a partnership between newly trained NMA investigators, Janssen & SOCS trial investigators/study coordinators, providing new investigators with the knowledge, support & confidence to continue thriving in clinical trial involvement. | This partnership aims to bridge the clinical trial experience gap. By facilitating a partnership between newly trained NMA investigators, Janssen & SOCS trial investigators/study coordinators, providing new investigators with the knowledge, support & confidence to continue thriving in clinical trial involvement. | |
| Jannsen | https://files.constantcontact.com/971a6f79001/683fc9c1-3815-4b49-837b-044bc7f7cb4c.png | PATIENT RECRUITMENT, ENGAGEMENT & COMMUNITY OUTREACH | https://www.hopkinsmedicine.org/fellowships/programs/dermatology/ethnic-skin-fellowship-program | The JHU Ethnic Skin Program Fellowship (ESP) | Janssen’s partnership with ESP addresses the unmet medical needs of skin of color (SOC) Patients by increasing and improving clinical care & advancing research, including training future dermatologists and researchers dedicated to treating skin diseases disproportionately impacting SOC minority populations. | Janssen’s partnership with ESP addresses the unmet medical needs of skin of color (SOC) Patients by increasing and improving clinical care & advancing research, including training future dermatologists and researchers dedicated to treating skin diseases disproportionately impacting SOC minority populations. | |
| GSK | https://www.gsk.com/media/8053/gsk-logo.png | PATIENT RECRUITMENT, ENGAGEMENT & COMMUNITY OUTREACH | https://www.gsk.com/en-gb/innovation/trials/diversity-in-clinical-trials/ | Diversity in Clinical Trials | GSK | Engaging with communities and advocacy groups to build trust, enhance awareness and provide education and outreach. | Engaging with communities and advocacy groups to build trust, enhance awareness and provide education and outreach. | |
| GSK | https://www.gsk.com/media/8053/gsk-logo.png | PATIENT RECRUITMENT, ENGAGEMENT & COMMUNITY OUTREACH | https://tigerlilyfoundation-mylivinglegacy.org/ | My Living Legacy: Empowering Communities as We Build Trust in Clinical Trials | My Living Legacy, created in partnership with the Tigerlily Foundation to empower Black and other BIPOC people to more deeply understand and trust in clinical trials and to consider clinical trials as a possible treatment option for life-threatening diseases like breast cancer. | My Living Legacy, created in partnership with the Tigerlily Foundation to empower Black and other BIPOC people to more deeply understand and trust in clinical trials and to consider clinical trials as a possible treatment option for life-threatening diseases like breast cancer. | |
| GSK | https://www.gsk.com/media/8053/gsk-logo.png | PATIENT RECRUITMENT, ENGAGEMENT & COMMUNITY OUTREACH | https://youtu.be/lzgkHXGDr3g | Improving Our Clinical Trial Diversity: Ovarian Cancer | Find out how GSK is working with organizations like MiOra to ensure that women from underserved communities are represented in clinical trials for Ovarian Cancer. | Find out how GSK is working with organizations like MiOra to ensure that women from underserved communities are represented in clinical trials for Ovarian Cancer. | |
| GSK | https://www.gsk.com/media/8053/gsk-logo.png | PATIENT RECRUITMENT, ENGAGEMENT & COMMUNITY OUTREACH | https://www.youtube.com/watch?v=JwapXtZ-gyM&t=209s | Improving Our Clinical Trial Diversity: Multiple Myeloma | Multiple Myeloma disproportionately impacts African Americans. To get ahead of this disease, we're working with patient advocates to increase the number of African American participants in clinical trials. | Multiple Myeloma disproportionately impacts African Americans. To get ahead of this disease, we're working with patient advocates to increase the number of African American participants in clinical trials. | |
| GSK | https://www.gsk.com/media/8053/gsk-logo.png | PATIENT RECRUITMENT, ENGAGEMENT & COMMUNITY OUTREACH | https://youtu.be/lzgkHXGDr3g | Improving Our Clinical Trial Diversity: Ovarian Cancer | Find out how GSK is working with organizations like MiOra to ensure that women from underserved communities are represented in clinical trials for Ovarian Cancer. | Find out how GSK is working with organizations like MiOra to ensure that women from underserved communities are represented in clinical trials for Ovarian Cancer. | |
| GSK | https://www.gsk.com/media/8053/gsk-logo.png | PATIENT RECRUITMENT, ENGAGEMENT & COMMUNITY OUTREACH | https://journals.sagepub.com/doi/10.1177/17407745221149118 | Demographic Diversity of US-Based Participants in GSK-Sponsored Interventional Clinical Trials | We investigate the racial and ethnic demographic diversity of US-based participants in GSK-sponsored interventional trials. We also assess the evaluation of demographic diversity against US Census and epidemiologic data. | We investigate the racial and ethnic demographic diversity of US-based participants in GSK-sponsored interventional trials. We also assess the evaluation of demographic diversity against US Census and epidemiologic data. | |
| Genetech | https://upload.wikimedia.org/wikipedia/commons/thumb/2/27/Genentech.svg/1200px-Genentech.svg.png | DATA TYPES (e.g., electronic health records) | https://www.gene.com/stories/pursuing-a-new-paradigm-in-inclusive-research | Trial Pathfinder | Results from a research collaboration between Genentech and Stanford known as Trial Pathfinder, published in the scientific journal Nature, highlight how real-world data and AI could be used to help address underrepresentation in clinical research for non-small cell lung cancer. | Results from a research collaboration between Genentech and Stanford known as Trial Pathfinder, published in the scientific journal Nature, highlight how real-world data and AI could be used to help address underrepresentation in clinical research for non-small cell lung cancer. | |
| Gilead | https://www.gilead.com/-/media/gilead-corporate/images/global/gilead-create-possible-svg | DATA TYPES (e.g., electronic health records) | https://stories.gilead.com/articles/stacey-bledsoe-resolve-to-make-clinical-trials-available-to-everyone | Stacey Bledsoe’s Resolve to Make Clinical Trials Available to Everyone | A nurse by training, Stacey asked his oncologist whether she could recommend a clinical trial, but despite being based at a major academic medical center, the physician didn’t know of any. | A nurse by training, Stacey asked his oncologist whether she could recommend a clinical trial, but despite being based at a major academic medical center, the physician didn’t know of any. | |
| Genetech | https://upload.wikimedia.org/wikipedia/commons/thumb/2/27/Genentech.svg/1200px-Genentech.svg.png | DATA TYPES (e.g., electronic health records) | https://www.gene.com/media/statements/ps_062321 | Advancing Inclusive Research® Site Alliance | This coalition of clinical research sites will partner with Genentech to advance the representation of diverse Patient populations in the company’s oncology clinical trials, test recruitment and retention approaches and establish best practices that can be leveraged across the industry to help achieve health equity for people with cancer. | This coalition of clinical research sites will partner with Genentech to advance the representation of diverse Patient populations in the company’s oncology clinical trials, test recruitment and retention approaches and establish best practices that can be leveraged across the industry to help achieve health equity for people with cancer. | |
| Genetech | https://upload.wikimedia.org/wikipedia/commons/thumb/2/27/Genentech.svg/1200px-Genentech.svg.png | DATA TYPES (e.g., electronic health records) | https://www.gene.com/stories/increasing-diversity-equity-and-inclusion-in-ophthalmology-research?topic=diversity-and-inclusion | Increasing Diversity, Equity And Inclusion In Ophthalmology Research | A first-of-its-kind retina study called Elevatum for underrepresented Patients with diabetic macular edema. | A first-of-its-kind retina study called Elevatum for underrepresented Patients with diabetic macular edema. | |
| FSG | https://www.fsg.org/wp-content/uploads/2021/08/logo.png | PATIENT RECRUITMENT, ENGAGEMENT & COMMUNITY OUTREACH | https://www.fsg.org/blog/advancing-health-equity-building-on-fda-requirement-for-clinical-trial-diversity/ | Advancing Health Equity: How Companies Can Build on the FDA’s Requirement for Clinical Trial Diversity | "Advancing Health Equity: How Companies Can Build on the FDA’s Requirement for Clinical Trial Diversity" was released March 2023. | "Advancing Health Equity: How Companies Can Build on the FDA’s Requirement for Clinical Trial Diversity" was released March 2023. | |
| Eli Lilly | https://upload.wikimedia.org/wikipedia/commons/thumb/1/1e/Lilly-Logo.svg/726px-Lilly-Logo.svg.png?20230221150444 | PATIENT RECRUITMENT, ENGAGEMENT & COMMUNITY OUTREACH | https://www.lilly.com/impact/access-to-medicines | Lilly 30x30 | Lilly 30x30 – to provide improved access to quality health care for 30 million people in resource-limited settings by 2030. https://www.facebook.com/watch/?v=2193548963994688 | Lilly 30x30 – to provide improved access to quality health care for 30 million people in resource-limited settings by 2030. https://www.facebook.com/watch/?v=2193548963994688 | |
| Insmed | https://insmed.com/wp-content/uploads/2021/11/logo.svg | PATIENT RECRUITMENT, ENGAGEMENT & COMMUNITY OUTREACH | https://njbiz.com/insmed-enlists-actress-seymour-to-tackle-unseenism-in-health-care/ | Insmed Enlists Actress Seymour to Tackle ‘Unseenism’ in Health Care | Insmed Inc. is teaming up with award-winning actress Jane Seymour for a campaign to raise awareness of gender and age biases in health care. | Insmed Inc. is teaming up with award-winning actress Jane Seymour for a campaign to raise awareness of gender and age biases in health care. | |
| Insmed | https://insmed.com/wp-content/uploads/2021/11/logo.svg | PATIENT RECRUITMENT, ENGAGEMENT & COMMUNITY OUTREACH | https://insmed.com/wp-content/uploads/2024/07/Clinical-Trial-Policy.Final_.pdf | Clinical Trial Policy Posted July 2024 | At Insmed, our commitment to run patient-focused, ethically conducted clinical trials is at the center of what we do. Included in our commitment is the delivery of high-quality trial data from Insmedsponsored trials to support our efforts to bring new treatments to underserved patient populations. | At Insmed, our commitment to run patient-focused, ethically conducted clinical trials is at the center of what we do. Included in our commitment is the delivery of high-quality trial data from Insmedsponsored trials to support our efforts to bring new treatments to underserved patient populations. | |
| IBM | https://upload.wikimedia.org/wikipedia/commons/thumb/5/51/IBM_logo.svg/1600px-IBM_logo.svg.png | PATIENT RECRUITMENT, ENGAGEMENT & COMMUNITY OUTREACH | https://www.ibm.com/think/topics/ai-for-clinical-trial-management | Redefining Clinical Trials: Adopting AI for Speed, Volume and Diversity | In this chapter of the IBM series on clinical trial innovation, we spotlight key strategies for boosting recruitment speed, helping to ensure diversity, and harnessing digital advancements. | In this chapter of the IBM series on clinical trial innovation, we spotlight key strategies for boosting recruitment speed, helping to ensure diversity, and harnessing digital advancements. | |
| IQVIA | https://bionj.org/wp-content/uploads/2023/12/IQVIA.png | PATIENT RECRUITMENT, ENGAGEMENT & COMMUNITY OUTREACH | https://www.iqvia.com/events/2023/04/designing-and-delivering-diversity-in-oncology-clinical-trials | Designing and Delivering Diversity in Oncology Clinical Trials | The IQVIA Institute has assembled a multi-stakeholder panel to explore the challenges, key levers and scenarios for consideration in oncology clinical trial diversity planning processes and in designing and delivering those trials. | The IQVIA Institute has assembled a multi-stakeholder panel to explore the challenges, key levers and scenarios for consideration in oncology clinical trial diversity planning processes and in designing and delivering those trials. | |
| IQVIA | https://bionj.org/wp-content/uploads/2023/12/IQVIA.png | PATIENT RECRUITMENT, ENGAGEMENT & COMMUNITY OUTREACH | https://www.iqvia.com/library/white-papers/leveraging-real-world-data-to-estimate-race-and-ethnicity-representation-in-clinical-trial-design | Leveraging Real-World Data to Estimate Race and Ethnicity Representation in Clinical Trial Design | IQVIA experts evaluate how best to set diversity goals and ensure clinical trials are more accessible by taking a proactive approach to diversity and inclusion that begins at the earliest stages of epidemiological review and protocol design. | IQVIA experts evaluate how best to set diversity goals and ensure clinical trials are more accessible by taking a proactive approach to diversity and inclusion that begins at the earliest stages of epidemiological review and protocol design. | |
| Eli Lilly | https://upload.wikimedia.org/wikipedia/commons/thumb/1/1e/Lilly-Logo.svg/726px-Lilly-Logo.svg.png?20230221150444 | PATIENT RECRUITMENT, ENGAGEMENT & COMMUNITY OUTREACH | https://www.lilly.com/impact/empowering-a-diverse-workforce | Empower A Diverse Workforce | We believe that by leveraging the varied backgrounds of our more than 35,000 employees – and by driving actionable and measurable strategies to improve DEI, including diversity within our clinical trials – we can better deliver scientific breakthroughs. | We believe that by leveraging the varied backgrounds of our more than 35,000 employees – and by driving actionable and measurable strategies to improve DEI, including diversity within our clinical trials – we can better deliver scientific breakthroughs. | |
| Eli Lilly | https://upload.wikimedia.org/wikipedia/commons/thumb/1/1e/Lilly-Logo.svg/726px-Lilly-Logo.svg.png?20230221150444 | PATIENT RECRUITMENT, ENGAGEMENT & COMMUNITY OUTREACH | https://www.lilly.com/impact/empowering-a-diverse-workforce | Lilly and EVA Pharma Collaborate to Expand Access to Baricitinib in Low- to Middle-Income Countries | Lilly will license certain baricitinib manufacturing know-how to enable EVA Pharma to manufacture and supply treatment for various immunological diseases across 49 low- to middle-income countries in Africa | Lilly will license certain baricitinib manufacturing know-how to enable EVA Pharma to manufacture and supply treatment for various immunological diseases across 49 low- to middle-income countries in | |
| Eli Lilly | https://upload.wikimedia.org/wikipedia/commons/thumb/1/1e/Lilly-Logo.svg/726px-Lilly-Logo.svg.png?20230221150444 | PATIENT RECRUITMENT, ENGAGEMENT & COMMUNITY OUTREACH | https://atlasclarity.com/lilly-and-nehi-present-equity-in-health-and-health-care-a-roadmap-to-collaborative-action/ | Lilly and Nehi Present Equity in Health and Health Care: A Roadmap to Collaborative Action | Despite major advancements in health care and medicine, disparities persist in access to health care and health outcomes among racial, ethnic, and other historically marginalized and underserved populations. The health care system is an interconnected ecosystem. Closing disparities requires systematic change and collaboration across a broad coalition of stakeholders. | Despite major advancements in health care and medicine, disparities persist in access to health care and health outcomes among racial, ethnic, and other historically marginalized and underserved populations. The health care system is an interconnected ecosystem. Closing disparities requires systematic change and collaboration across a broad coalition of stakeholders. | |
| Eli Lilly | https://upload.wikimedia.org/wikipedia/commons/thumb/1/1e/Lilly-Logo.svg/726px-Lilly-Logo.svg.png?20230221150444 | PATIENT RECRUITMENT, ENGAGEMENT & COMMUNITY OUTREACH | https://youtu.be/qYOe8lFnPJA | Dreaming Big: The Future of Mobile Research | At the height of the COVID-19 pandemic, we launched mobile research RVs to test a potential COVID therapy in nursing homes across the U.S. Now we’re expanding our fleet of mobile units to improve access to other clinical studies—and transform how we research potential new medicines. | At the height of the COVID-19 pandemic, we launched mobile research RVs to test a potential COVID therapy in nursing homes across the U.S. Now we’re expanding our fleet of mobile units to improve access to other clinical studies—and transform how we research potential new medicines. | |
| Eli Lilly | https://upload.wikimedia.org/wikipedia/commons/thumb/1/1e/Lilly-Logo.svg/726px-Lilly-Logo.svg.png?20230221150444 | PATIENT RECRUITMENT, ENGAGEMENT & COMMUNITY OUTREACH | https://investor.lilly.com/news-releases/news-release-details/more-two-thirds-people-atopic-dermatitis-and-skin-color | More than two-thirds of people with atopic dermatitis and skin of color experienced skin improvement in a first-of-its-kind lebrikizumab study | Eli Lilly and Company announced results from a first-of-its-kind study of lebrikizumab specifically designed for people with skin of color and moderate-to-severe atopic dermatitis, commonly called eczema. In this study, treatment with lebrikizumab, an investigational medicine, showed improvement in skin clearance and itch relief. | Eli | |
| Eli Lilly | https://upload.wikimedia.org/wikipedia/commons/thumb/1/1e/Lilly-Logo.svg/726px-Lilly-Logo.svg.png?20230221150444 | PATIENT RECRUITMENT, ENGAGEMENT & COMMUNITY OUTREACH | https://investor.lilly.com/news-releases/news-release-details/lillys-social-impact-venture-capital-portfolio-poised-grow-300 | Lilly's Social Impact Venture Capital Portfolio Poised | Lilly has allocated an additional $50 million to its $300 million Social Impact Venture Capital Portfolio in efforts to combat racial injustice and its effects on Black Americans and historically marginalized communities in the U.S. | Lilly has allocated an additional $50 million to its $300 million Social Impact Venture Capital Portfolio in efforts to combat racial injustice and its effects on Black Americans and historically marginalized communities in the U.S. | |
| Eli Lilly | https://upload.wikimedia.org/wikipedia/commons/thumb/1/1e/Lilly-Logo.svg/726px-Lilly-Logo.svg.png?20230221150444 | PATIENT RECRUITMENT, ENGAGEMENT & COMMUNITY OUTREACH | https://investor.lilly.com/news-releases/news-release-details/lilly-unicef-expand-support-help-millions-young-people-risk | Lilly, UNICEF Expand Support to Help Millions of Young People at Risk of Noncommunicable Diseases | During the World Health Assembly today, Eli Lilly and Company (NYSE: LLY) announced it will donate $6.5 million to the United States Fund for UNICEF to expand UNICEF's work to improve the health outcomes of millions of children and youth at risk of noncommunicable diseases (NCDs) living in resource-limited settings in India. This will bring the company's total commitment since 2022 to more than $20 million. | During the | |
| Deloitte | https://www2.deloitte.com/content/dam/assets/logos/Deloitte_logo_PRI.svg | DATA TYPES (e.g., electronic health records) | https://www2.deloitte.com/us/en/insights/industry/health-care/racial-bias-health-care-algorithms.html | Bias in Health Care Delivery can be Addressed Through a System-Level Approach to Data, Algorithms and Technologies | Lack of data standards makes addressing system-level biases challenging — including collecting data on race/ethnicity, the misuse of racial/ethnic data to inform treatment/diagnosis & algorithms that inappropriately account for race factors. | Lack of data standards makes addressing system-level biases challenging — including collecting data on race/ethnicity, the misuse of racial/ethnic data to inform treatment/diagnosis & algorithms that inappropriately account for race factors. | |
| Deloitte | https://www2.deloitte.com/content/dam/assets/logos/Deloitte_logo_PRI.svg | DATA TYPES (e.g., electronic health records) | https://www2.deloitte.com/us/en/insights/industry/health-care/increasing-diversity-clinical-trials.html | Broadening Clinical Trial Participation to Improve Health Equity | Community-based organizations can help reach a broader population and enhance clinical trial diversity. Discover how to meet consumers where they are. | Community-based organizations can help reach a broader population and enhance clinical trial diversity. Discover how to meet consumers where they are. | |
| Deloitte | https://www2.deloitte.com/content/dam/assets/logos/Deloitte_logo_PRI.svg | DATA TYPES (e.g., electronic health records) | https://www2.deloitte.com/us/en/insights/industry/life-sciences/lack-of-diversity-clinical-trials.html | Enhancing Clinical Trial Diversity | Stakeholder perspectives on advancing research through representative clinical trials | Stakeholder perspectives on advancing research through representative clinical trials. | |
| Deloitte | https://www2.deloitte.com/content/dam/assets/logos/Deloitte_logo_PRI.svg | DATA TYPES (e.g., electronic health records) | https://www2.deloitte.com/us/en/insights/industry/health-care/community-based-inclusive-and-equitable-clinical-trials.html | Broadening Research Participation Through Community Engagement | Community Health Centers can help increase the diversity and scope of clinical studies—and ultimately, improve patient outcomes. | Community Health Centers can help increase the diversity and scope of clinical studies—and ultimately, improve patient outcomes. | |
| Deloitte | https://www2.deloitte.com/content/dam/assets/logos/Deloitte_logo_PRI.svg | PATIENT RECRUITMENT, ENGAGEMENT & COMMUNITY OUTREACH | https://www2.deloitte.com/us/en/pages/life-sciences-and-health-care/articles/free-public-health-equity-data.html | Deloitte Health Equity Dashboard | The Deloitte Health Equity Dashboard can support individuals and local, regional and national organizations to better understand communities in need. | The Deloitte Health Equity Dashboard can support individuals and local, regional and national organizations to better understand communities in need. | |
| Deloitte | https://www2.deloitte.com/content/dam/assets/logos/Deloitte_logo_PRI.svg | PATIENT RECRUITMENT, ENGAGEMENT & COMMUNITY OUTREACH | https://www2.deloitte.com/us/en/insights/industry/health-care/strategies-for-health-equity.html?id=us:2sm:3li:4diUS175982:5awa:6di:MMDDYY:author&pkid=1011049 | Achieving Health Equity in Life Sciences | With a companywide approach to health equity, life sciences companies can develop more equitable products and services—and see better health outcomes and tangible business benefits. | With a companywide approach to health equity, life sciences companies can develop more equitable products and services—and see better health outcomes and tangible business benefits. | |
| Deloitte | https://www2.deloitte.com/content/dam/assets/logos/Deloitte_logo_PRI.svg | PATIENT RECRUITMENT, ENGAGEMENT & COMMUNITY OUTREACH | https://www2.deloitte.com/us/en/blog/health-care-blog/2022/using-ai-to-accelerate-clinical-trials.html | Using AI to Accelerate Clinical Trials | Unlocking the Potential: AI's game-changing role in life sciences accelerates drug development, streamlining clinical trials for faster delivery of life-saving treatments. | Unlocking the Potential: AI's game-changing role in life sciences accelerates drug development, streamlining clinical trials for faster delivery of life-saving treatments. | |
| Crossroads 4 Hope | https://crossroads4hope.org/wp-content/uploads/2023/01/Crossroads4Hope-Logo-new-copy-NX-1.png | PATIENT RECRUITMENT, ENGAGEMENT & COMMUNITY OUTREACH | https://crossroads4hope.org/outreach-initiative/ | Building Community Resilience: Closing The Cancer Care Gap | Crossroads4Hope helps save lives by closing the cancer care gap in vulnerable communities, activating Health Champions as “First Responders” who normalize conversations around cancer, treatment decision-making and clinical trials. | Crossroads4Hope helps save lives by closing the cancer care gap in vulnerable communities, activating Health Champions as “First Responders” who normalize conversations around cancer, treatment decision-making and clinical trials. | |
| Bristol Myers Squibb | https://s25.q4cdn.com/566753351/files/design/bms-rebrand-logo.svg | WORKFORCE DEVELOPMENT (e.g., investigator education & diversity) | https://diversityinclinicaltrials.org | Robert A. Winn Diversity in Clinical Trials Award Program (Bristol Myers Squibb Foundation) | The program aims to transform the U.S. clinical research landscape by training 250 new, community-oriented clinical trialists, to bring in the community voice at every phase of clinical and translational research, and increase DICT. | The program aims to transform the U.S. clinical research landscape by training 250 new, community-oriented clinical trialists, to bring in the community voice at every phase of clinical and translational research, and increase DICT. | |
| Bristol Myers Squibb | https://s25.q4cdn.com/566753351/files/design/bms-rebrand-logo.svg | WORKFORCE DEVELOPMENT (e.g., investigator education & diversity) | https://news.bms.com/news/philanthropy/2023/Bristol-Myers-Squibb-Announces-Progress-Toward-Long-Term-Inclusion--Diversity-Goals-and-Health-Equity-Commitments/default.aspx | Bristol Myers Squibb Inclusion & Diversity and Health Equity Commitments (Diversity in Clinical Trials Goal) | In 2020, BMS set I&D and health equity goals including one for diversity in clinical trials which aimed to locate 25% BMS clinical trials in the United States in racially and ethnically diverse communities by 2022 and 58% has been achieved to date | In 2020, BMS set I&D and health equity goals including one for diversity in clinical trials which aimed to locate 25% BMS clinical trials in the United States in racially and ethnically diverse communities by 2022 and 58% has been achieved to date | |
| Bristol Myers Squibb | https://s25.q4cdn.com/566753351/files/design/bms-rebrand-logo.svg | WORKFORCE DEVELOPMENT (e.g., investigator education & diversity) | https://www.bms.com/life-and-science/news-and-perspectives/patient-engagement-and-clinical-trial-diversity.html | Patient Expert Engagement Resource (PEER) | Bristol Myers Squibb works with Patient advocates through PEER to formally incorporate Patient voices at every stage in R&D and commercialization. All pivotal trial protocols must include expert Patient advocate engagement for sign off. | Bristol Myers Squibb works with Patient advocates through PEER to formally incorporate Patient voices at every stage in R&D and commercialization. All pivotal trial protocols must include expert Patient advocate engagement for sign off. | |
| Bristol Myers Squibb | https://s25.q4cdn.com/566753351/files/design/bms-rebrand-logo.svg | WORKFORCE DEVELOPMENT (e.g., investigator education & diversity) | https://news.bms.com/news/details/2022/Bristol-Myers-Squibb-Launches-Disability-Diversity-in-Clinical-Trials-DDiCT-Initiative-to-Improve-Healthcare-Outcomes-for-People-with-Disabilities/default.aspx | Disability Diversity in Clinical Trials (DDiCT) Initiative | The initiative initially aims to make recommendations on how to effectively improve access, engagement, speed of enrollment and participation of people with disabilities in clinical trials in collaboration with Disability Solutions. | The initiative initially aims to make recommendations on how to effectively improve access, engagement, speed of enrollment and participation of people with disabilities in clinical trials in collaboration with Disability Solutions. | |
| Bristol Myers Squibb | https://s25.q4cdn.com/566753351/files/design/bms-rebrand-logo.svg | WORKFORCE DEVELOPMENT (e.g., investigator education & diversity) | https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html | SOGI data collection in clinical trials | In 2022, the company launched an initiative to collect voluntary Patient gender self-identification data in clinical trials to improve culturally competent care for LGBT patients and increase inclusive research and DICT. | Clinical trials and research are a critical part of bringing new medicines to patients. Through the data generated from clinical trials, we answer important scientific questions and gain a better understanding about the efficacy and safety of these study medicines and their potential as treatment options for patients. | |
| Biomarin | https://www.biomarin.com/wp-content/uploads/2023/09/logo-biomarin.svg | PATIENT RECRUITMENT, ENGAGEMENT & COMMUNITY OUTREACH | https://www.biomarin.com/our-company/corporate-social-responsibility/diversity-equity-inclusion/clinical-trial-diversity/ | BioMarin CTD Working Group | A CTD Working Group, comprised of cross-functional leaders in clinical trial design and conduct. | A CTD Working Group, comprised of cross-functional leaders in clinical trial design and conduct. | |
| Biogen | https://www.biogen.com/content/dam/corporate/international/global/en-US/global/logos/biogen-logo-colour.svg | PATIENT RECRUITMENT, ENGAGEMENT & COMMUNITY OUTREACH | https://www.biogen.com/stories/tufts-clinical-trial.html | A Collaboration with Tufts Center for the Study of Drug Development | The study investigated ways to potentially help improve a fundamental step in future healthcare outcomes — clinical trials. | The study investigated ways to potentially help improve a fundamental step in future healthcare outcomes — clinical trials. | |
| ASCPT | https://files.constantcontact.com/971a6f79001/6fb9a9a1-e5f4-4518-89d2-80cb83a38532.png | TRIAL SPONSOR (e.g., influence study & protocol design) | https://ascpt.onlinelibrary.wiley.com/doi/10.1002/cpt.2819 | The Clinical Trials Transformation Initiative | The Clinical Trials Transformation Initiative (CTTI)—a public-private partnership between Duke University and the FDA—investigated existing organizational-level diversity and inclusion practices among institutions who sponsor and lead clinical trials of investigational medical products. | The Clinical Trials Transformation Initiative (CTTI)—a public-private partnership between Duke University and the FDA—investigated existing organizational-level diversity and inclusion practices among institutions who sponsor and lead clinical trials of investigational medical products. | |
| Amicus | https://amicusrx.com//wp-content/uploads/2017/09/logo.png | PATIENT RECRUITMENT, ENGAGEMENT & COMMUNITY OUTREACH | https://amicusrx.com/wp-content/uploads/2023/04/Amicus-ESG2023-FINAL.pdf | Assessing Capacity for Diverse Rare Disease Clinical Trials | We are currently assessing our capacity for supporting diversity in rare disease clinical trials across our partner sites. We have also solicited RFPs from vendors with a strong background in supporting diverse clinical trial recruitment. | We are currently assessing our capacity for supporting diversity in rare disease clinical trials across our partner sites. We have also solicited RFPs from vendors with a strong background in supporting diverse clinical trial recruitment. | |
| Amagen | https://www.amgen.com/-/media/Themes/CorporateAffairs/amgen-com/amgen-com/images/amgencommigration/Common/amgen-blue.svg?la=en&hash=7D2AC78653B168ACF5B939261E70935F | PATIENT RECRUITMENT, ENGAGEMENT & COMMUNITY OUTREACH | https://www.amgen.com/stories/2021/05/-/media/Themes/CorporateAffairs/amgen-com/amgen-com/images/amgencommigration/stories/2021/05-10-Building-Partnerships-to-Disrupt-Health-Barriers/2021-Amgen-Health-Equity-Summit-Exec-Summary-FINAL.pdf | Disrupting Health Disparities Through Partnership | Amgen's Summit, Disrupting Health Disparities Through Partnership, brought together a wide range of experts to discuss issues around racial equity in healthcare. | Amgen's Summit, Disrupting Health Disparities Through Partnership, brought together a wide range of experts to discuss issues around racial equity in healthcare. | |
| Amagen | https://www.amgen.com/-/media/Themes/CorporateAffairs/amgen-com/amgen-com/images/amgencommigration/Common/amgen-blue.svg?la=en&hash=7D2AC78653B168ACF5B939261E70935F | PATIENT RECRUITMENT, ENGAGEMENT & COMMUNITY OUTREACH | https://www.amgen.com/stories/2021/02/inside-amgens-push-for-greater-diversity-in-clinical-trials | RISE (Representation in ClInical ReSEarch) | RISE (Representation in ClInical ReSEarch) is a team dedicated to addressing the systemic issues that deter people from participating in research, especially those who have been historically excluded due to race, ethnicity, sex, age and other factors. | RISE (Representation in ClInical ReSEarch) is a team dedicated to addressing the systemic issues that deter people from participating in research, especially those who have been historically excluded due to race, ethnicity, sex, age and other factors. | |
| Abbvie | https://www.abbvie.com/content/dam/abbvie-com2/images/logos/abbvie-logo-header.svg | PATIENT RECRUITMENT, ENGAGEMENT & COMMUNITY OUTREACH | https://www.abbvie.com/who-we-are/our-stories/are-your-needs-represented-in-clinical-trials.html | Meet Patients Where They Are | Clinical trial participation should reflect the Patient population affected by the disease. AbbVie's head of diversity and Patient inclusion looks at what needs to be done to progress future clinical research efforts. | Clinical trial participation should reflect the Patient population affected by the disease. AbbVie's head of diversity and Patient inclusion looks at what needs to be done to progress future clinical research efforts. | |
| Abbott | https://upload.wikimedia.org/wikipedia/commons/thumb/a/a4/Abbott_Laboratories_logo.svg/800px-Abbott_Laboratories_logo.svg.png?20200420035815 | WORKFORCE DEVELOPMENT (e.g., investigator education & diversity) | https://www.abbott.com/corpnewsroom/sustainability/new-scholarships-support-diverse-researchers-of-the-future.html | Abbott Scholars Scholarship | Abbott commits $5 million to fund nearly 300 scholarships through new partnerships with medical schools at historically black colleges and universities (HBCUs) and nursing associations. | Abbott commits $5 million to fund nearly 300 scholarships through new partnerships with medical schools at historically black colleges and universities (HBCUs) and nursing associations. | |
| Abbott | https://upload.wikimedia.org/wikipedia/commons/thumb/a/a4/Abbott_Laboratories_logo.svg/800px-Abbott_Laboratories_logo.svg.png?20200420035815 | WORKFORCE DEVELOPMENT (e.g., investigator education & diversity) | https://abbott.mediaroom.com/2022-05-11-Abbott-and-Women-as-One-Partner-to-Help-More-Underrepresented-Physicians-Lead-Clinical-Trials | Abbott and Women as One Partner to Help More Underrepresented Physicians Lead Clinical Trials | Abbott partnered with Women as One to train more female and underrepresented physicians to pursue clinical trial research and help recruit clinical trial participants from historically underrepresented groups. | Abbott partnered with Women as One to train more female and underrepresented physicians to pursue clinical trial research and help recruit clinical trial participants from historically underrepresented groups. | |
| Abbott | https://upload.wikimedia.org/wikipedia/commons/thumb/a/a4/Abbott_Laboratories_logo.svg/800px-Abbott_Laboratories_logo.svg.png?20200420035815 | WORKFORCE DEVELOPMENT (e.g., investigator education & diversity) | https://www.abbott.com/corpnewsroom/sustainability/case-study-clinical-trial-diversity-for-life-btk.html | Case Study: Clinical Trial Diversity for LIFE-BTK | A case study of recruiting Patients in underserved communities. | A case study of recruiting Patients in underserved communities. | |
| AAHCI | https://files.constantcontact.com/971a6f79001/b7abfd5b-d09d-4267-bc38-f7afbc7fa1ac.png | WORKFORCE DEVELOPMENT (e.g., investigator education & diversity) | https://www.aahcdc.org/Publications-Resources/Series/Connecting-Pipelines-to-Pathways-for-Health-Equity-Case-Studies | Connecting Pipelines to Pathways for Health Equity: Case Studies | This series of case studies in the Academic Health Center Best Practices showcase pipeline & pathway programs developed at academic health centers to inspire and support learners to enter health professions and biomedical sciences careers. Each case study details a specific challenge, the institution’s response, key takeaways and outcomes. | This series of case studies in the Academic Health Center Best Practices showcase pipeline & pathway programs developed at academic health centers to inspire and support learners to enter health professions and biomedical sciences careers. Each case study details a specific challenge, the institution’s response, key takeaways and outcomes. | |
| AAFP5 | https://files.constantcontact.com/971a6f79001/cdce8ee8-8cff-44df-90e8-37d60d0b17c5.png | PATIENT RECRUITMENT, ENGAGEMENT & COMMUNITY OUTREACH | https://www.aafp.org/pubs/fpm/issues/2023/0300/health-equity.html | Case Studies in Innovative Community Engagement to Improve Health Equity in Cardiovascular Disease | Beginning in March 2021, the American Academy of Family Physicians (AAFP) implemented a two-year project to address cardiovascular disparities in African American communities, with a focus on atrial fibrillation (AFib). | Beginning in March 2021, the American Academy of Family Physicians (AAFP) implemented a two-year project to address cardiovascular disparities in African American communities, with a focus on atrial fibrillation (AFib). |
